Advertisement

Wiener Medizinische Wochenschrift

, Volume 165, Issue 19–20, pp 387–394 | Cite as

Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement

  • Edgar PetruEmail author
  • Christian F. Singer
  • Stephan Polterauer
  • Arik Galid
  • Christian Schauer
  • Johann Klocker
  • Michael Seifert
  • Alexander Reinthaller
  • Christoph Benedicic
  • Michael Hubalek
  • Lukas Hefler
  • Christian Marth
  • Tonja Scholl-Firon
  • Gerhard Bogner
  • Alain-Gustave Zeimet
review

Summary

We reviewed the status of the use of the prophylactic long-acting granulocyte colony-stimulating factors (G-CSFs) pegfilgrastim and lipegfilgrastim in gynecologic malignancies. Long-acting G-CSFs should not be used in weekly regimens. Filgrastim is not indicated in patients with febrile and/or severe neutropenia after administration of long-acting G-CSF in the same cycle. One study has shown a moderate effect on febrile neutropenia of ciprofloxacin when co-administered with pegfilgrastim. There is broad evidence from meta-analyses that pegfilgrastim effectively reduces severe neutropenia. In parallel, its adverse effects have been studied extensively. All-cause mortality was significantly reduced by pegfilgrastim. The glycopegylated long-acting G-CSF, lipegfilgrastim has demonstrated antineutropenic efficacy similar to that of pegfilgrastimin in one breast cancer study. In another pivitol non-small cell lung cancer study, impaired survival was observed in the lipegfilgrastim group during the first 30 days of study. The European Medicines Agency claimed more profound safety data to be provided for lipegfilgrastim by 2017.

Keywords

Granulocyte colony-stimulating factors (G-CSF) Long-acting granulocyte colony stimulating factors Chemotherapy-induced neutropenia Febrile neutropenia Gynecologic cancer 

Prophylaxe mit langwirksamen Granulozyten-Kolonie-stimulierenden Faktoren (G-CSF) bei gynäkologischen Malignomen

Zusammenfassung

Der aktuelle Status der prophylaktischen langwirksamen Granulozyten Kolonie-stimulierender Faktoren (G-CSFs) Pegfilgrastim and Lipegfilgrastim bei gynäkologischen Malignomen wurde zusammengefasst. Langwirksame G-CSFs sollten nicht bei wöchentlichen Chemotherapien angewendet werden. Konventionelles Filgrastim ist bei Patienten mit febriler und/oder schwerer Neutropenie nach Anwendung langwirksamer G-CSF im gleichen Zyklus nicht indiziert. Eine Studie hat einen moderaten Effekt der Begleittherapie von Ciprofloxacin zusätzlich zu Pegfilgrastim auf die febrile Neutropenie gezeigt. Es existiert breite Evidenz auf der Basis großer Studien und Metaanalysen, dass Pegfilgrastim die schwere Neutropenie signifikant reduziert. Parallel wurden seine Nebenwirkungen wie Knochenschmerzen im Detail untersucht. Die Gesamtmortalität wird durch Pegfilgrastim signifikant reduziert. Das andere glykopegylierte langwirksame G-CSF, Lipegfilgrastim, hat eine Pegfilgrastim vergleichbare antineutropenische Effektivität in einer Brustkrebsstudie gezeigt. In der anderen Zulassungsstudie beim nichtkleinzelligen Bronchuskarzinom wurde während der ersten 30 Tage der Studie gegenüber Plazebo ein schlechteres Überleben in der Lipegfilgrastimgruppe beobachtet. Die Europäische Medizinagentur fordert daher vertiefte Sicherheitsdaten für Lipegfilgrastim bis 2017.

Schlüsselwörter

Granulozyten Kolonie-stimulierende Faktoren (G CSF) Langwirksame Granulozyten-Kolonie stimulierende Faktoren Chemotherapie-induzierte Neutropenie Febrile Neutropenie Gynäkologische Karzinome 

References

  1. 1.
    Aapro MS, Bohlius J, Cameron D, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte colony stimulating factors to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Crawford J, Caserta C, Roila F. Haematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010;21 (Suppl 5) v246–51.Google Scholar
  3. 3.
    Von Minckwitz G, Kümmel S, DuBois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M; German Breast Group. Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292–8.CrossRefGoogle Scholar
  4. 4.
    Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a spanish breast cancer research group (GEICAM-9903) phase III study. J Clin Oncol. 2004;22(13):2587–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198–212.CrossRefPubMedGoogle Scholar
  6. 6.
    Timmer-Bonte J, Adang E, Smit H, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VC. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24(19):2991–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Germany guideline AGO. http://www.ago-online.de/.
  8. 8.
    De Naurois J, Novitzky-Basso I, Gill M, Marti Marti F, Cullen M, Rolla F. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010; 21 (Suppl 5) v252–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.CrossRefPubMedGoogle Scholar
  10. 10.
    NCCN clinical practice guidelines in oncology. Myeloid growth factors. Version 2.2014.Google Scholar
  11. 11.
    Crawford J, Allen J, Armitage J, Balducci L, Becker P, Blayney D, Cataland S, Heaney M, Hudock S, Kloth D, Kuter D, Lyman G, McMahon B. Myeloid Growth Factors. JNCCN. 2011;9:1266–90.Google Scholar
  12. 12.
    Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the european organization for research and treatment of cancer 10961 multicenter phase III trial. J Clin Oncol. 2002;20:3114–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Hensley M, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresesctable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–31.CrossRefPubMedGoogle Scholar
  14. 14.
    Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P; TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968–75.CrossRefPubMedGoogle Scholar
  15. 15.
    Petru E, Zeimet AG, Sevelda P, Seifert M, Singer C, Hubalek M, Angleitner-Boubenizek L, Speiser P, Benedicic C, Stummvoll W, Reinthaller A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO). Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer. Wien Klin Wochenschr. 2012;124:412–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Citron ML, Berry D, Cirrincione, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukaemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–84.CrossRefPubMedGoogle Scholar
  18. 18.
    Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35.CrossRefPubMedGoogle Scholar
  19. 19.
    Holmes FA, Jones SE, O’Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Bondarenko I, Gladkov O, Elaesser R, Buchner A, Bias P. Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. J Clin Oncol. 2012;30 (Suppl Abstr e19587).Google Scholar
  21. 21.
    Volovat C, Gladkov OA, Bondarenko IM, Barash S, Buchner A, Avisar N, Bias P, Mueller U. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. International MASCC/ISOO Symposium, 2012;20 (pp S235–S236).Google Scholar
  22. 22.
    Lyman G, Dale D, Wolff D, Culakova E, Poniewierski MS, Kuderer NM, Crawford J. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010a;28:2914–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010b;116:5555–63.CrossRefPubMedGoogle Scholar
  24. 24.
    Lyman GH. Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol. 2003;30(4 Suppl 13):10–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Sierra J, Harms R, Mo M, Vogel C. Evaluation of reported bone pain in patients receiving chemotherapy in pegfilgrastim clinical trials. J Clin Oncol. 2009;27:15S (Suppl; Abstr 9621).Google Scholar
  26. 26.
    Kubista E, Glaspy J, Holmes F, et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003;3:391–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Schwartzberg L, Mo M, Harms R, Vogel C. Reported bone pain in patients with breast cancer receiving taxane-based chemotherapy in clinical trials of pegfilgrastim. Cancer Res. 2009;69:(Suppl 24) (Abstr 1117).Google Scholar
  28. 28.
    Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opinion. 2007;23:2283–95.CrossRefGoogle Scholar
  29. 29.
    Kirshner J, Heckler E, Dakhil S, et al. Prevention of pegfilgrastim-induced bone pain: A URCC CCOP randomized, double-blind, placebo-controlled trial of 510 cancer patients. J Clin Oncol. 2010;28. (Suppl 639 s Abstr 9014).Google Scholar
  30. 30.
    Fachinformation Neulasta® August 2014.Google Scholar
  31. 31.
    Leitgeb C. Quality of life and cytokines in oncological therapy. Wien Med Wochenschr. 1998;148:424–6.PubMedGoogle Scholar
  32. 32.
    Cooper K, Madan J, Whyte S, Stevenson M, Akehurst R. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–67.CrossRefPubMedGoogle Scholar
  34. 34.
    Gregory S, Schwartzberg L, Mo M, Sierra J, Vogel C. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncol. 2010;7:297–306.CrossRefGoogle Scholar
  35. 35.
    Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416–24.CrossRefPubMedGoogle Scholar
  36. 36.
    European Medicines Agency. Assessment report Lonquex. Procedure No. EMEA/H/C/002556/0000.Google Scholar
  37. 37.
    De Boer RH, Patterson WK, Beith J, Lynch J, Selva S, Rocchi L, Beer F, Lewis CR. Eur J Cancer. 2008;6:128(Suppl Abstr 269).CrossRefGoogle Scholar
  38. 38.
    Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract. 2010;6:133–40.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23:8340–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Mattioli R, Gridelli C, Castellanos J, Duque A, Falcone A, Mansutti M, Bacon P, Lawrinson S, Skacel T, Casas A. Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. Clin Transl Oncol. 2009;11:842–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist. 2007;12:484–94.CrossRefPubMedGoogle Scholar
  42. 42.
    Romieu G, Clemens M, Mahlberg R, Fargeot P, Constenla M, Schütte M, Easton V, Skacel T, Bacon P, Brugger W. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol. 2007;64:64–72.CrossRefPubMedGoogle Scholar
  43. 43.
    Buchner A, Bias P, Kaufmann M. A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy. J Clin Oncol. 2011;29 (Suppl Abstr 9080).Google Scholar
  44. 44.
    Johnston E, Crawford J, Blackwell, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522–8.PubMedGoogle Scholar
  45. 45.
    Smith F. Neutropenia and anxiety in advance non-small cell lung cancer patients: Initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenia complications. J Clin Oncol 2005;23 (Suppl Abstr 8173).Google Scholar
  46. 46.
    Willis F, Woll P, Theti D, Jamali H, Bacon P, Baker N, Pettengell R. Pegfilgrastim for peripheral CD34 + mobilization in patients with solid tumours. Bone Marrow Transplant. 2009;43:927–34.CrossRefPubMedGoogle Scholar
  47. 47.
    Gladkov O, Bondarenko I, Elsaesser R, Buchner A, Bias P. Absolute neutrophil counts in a study of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. Ann Oncol. 23 (Suppl 9) ix500. (Abstr. 1548PD).Google Scholar
  48. 48.
    Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496–502.PubMedGoogle Scholar
  49. 49.
    George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1691–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J. Hiddemann W, International Study Group. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1503–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Lopez A. Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: arandomised phase II study. Blood. 2004;104:904A–5A.CrossRefGoogle Scholar
  52. 52.
    Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy. Haematologica. 2008;93:405–12.CrossRefPubMedGoogle Scholar
  53. 53.
    Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21:514–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Wolf M, Bentley M, Marlton P, Horvath N, Lewis ID, Spencer A, Herrmann R, Arthur C, Durrant S, van Kerkhoven M, MacMillan J, Mrongovius R. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2006;47:2344–50.CrossRefPubMedGoogle Scholar
  55. 55.
    Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010;9:95–101.CrossRefPubMedGoogle Scholar
  56. 56.
    Pirker R, Ulsperger E, Messner J, Aigner K, Forstner B, Bacon P, Easton V, Skacel T. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung. 2006;184:279–85.CrossRefPubMedGoogle Scholar
  57. 57.
    Engert A, Bredenfeld H, Döhner H, Ho AD, Schmitz N, Berger D, Bacon P, Skacel T, Easton V, Diehl V. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica. 2006;91:546–9.PubMedGoogle Scholar
  58. 58.
    Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer. 2008;8:195.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H, Bargou RC. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113:4137–43.CrossRefPubMedGoogle Scholar
  60. 60.
    Spunt SL, Irving H, Frost J, Sender L, Guo M, Yang BB, Dreiling L, Santana VM. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol. 2010;28(8):1329–36.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2015

Authors and Affiliations

  • Edgar Petru
    • 1
    Email author
  • Christian F. Singer
    • 2
  • Stephan Polterauer
    • 2
  • Arik Galid
    • 3
  • Christian Schauer
    • 4
  • Johann Klocker
    • 5
  • Michael Seifert
    • 2
  • Alexander Reinthaller
    • 2
  • Christoph Benedicic
    • 1
  • Michael Hubalek
    • 6
  • Lukas Hefler
    • 7
  • Christian Marth
    • 6
  • Tonja Scholl-Firon
    • 8
  • Gerhard Bogner
    • 9
  • Alain-Gustave Zeimet
    • 6
  1. 1.Division of Gynecology, Department of Obstetrics and GynecologyMedical University of GrazGrazAustria
  2. 2.Department of Obstetrics and GynecologyMedical University of ViennaViennaAustria
  3. 3.Department of Obstetrics and GynecologyHanuschkrankenhausViennaAustria
  4. 4.Department of GynecologyHospital Barmherzige Brüder GrazGrazAustria
  5. 5.Department of Internal MedicineKlinikum KlagenfurtKlagenfurtAustria
  6. 6.Department of Obstetrics and GynecologyMedical University of InnsbruckInnsbruckAustria
  7. 7.Department of GynecologyHospital Barmherzige SchwesternLinzAustria
  8. 8.Department of Obstetrics and GynecologyWilhelminenspitalViennaAustria
  9. 9.Department of Obstetrics and GynecologyParacelsus University of SalzburgSalzburgAustria

Personalised recommendations